Pharmafile Logo
Pharmafocus logo
Advanced Search

MSD

Showing 15 posts of 247 posts found.

Lung xray image

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070

August 7, 2024
Research and Development Daiichi Sankyo, MSD, Merck, Oncology, antibody drug conjugate, neuroendocrine cancer, oncology, small cell lung cancer

Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced the expansion of their co-development …

News

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024
Research and Development Gastric, MSD, Merck, Oncology, keytruda

Merck, known as MSD outside of the US and Canada, has announced data from the phase 3 KEYNOTE-811 trial which …

News

Merck to acquire Harpoon Therapeutics for approximately $680m

January 10, 2024
Business Services Harpoon Therapeutics, MSD, Merck, Oncology, acquisition

Merck (known as MSD outside of the US and Canada) and Harpoon Therapeutics have announced that they have entered a …

News
markus-spiske-hvsr_cvecvi-unsplash

Owkin and Merck enter collaboration agreement for AI-powered cancer diagnostics

December 20, 2023
Research and Development AI diagnostics, Cancer, MSD, Merck, Oncology, Owkin

Owkin and Merck, known as MSD outside of the US and Canada, have announced that they have entered into a …

News

Merck to acquire Caraway Therapeutics for up to $610m

November 22, 2023
Business Services Caraway Therapeutics, MSD, Merck, Pharmacy, acquisition

Merck (known as MSD outside of the US and Canada) and Caraway Therapeutics have announced that they have entered into …

News

FDA approves Merck’s Keytruda for gastric cancer treatment

November 17, 2023
Medical Communications FDA, MSD, Merck, Oncology, gastric cancer, keytruda

Merck, known as MSD outside of the US, has announced that the US Food and Drug Administration (FDA) has approved …

News
cancer_cells_from_the_breast_cancer_now_tissue_bank_cell_programme

Merck shares data from phase 3 trial for breast cancer treatment

August 1, 2023
Research and Development MSD, Merck, Oncology, breast cancer, keytruda

Merck, also known as MSD outside of the US and Canada, has announced positive results from the phase 3 KEYNOTE-756 …

News

AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment

June 9, 2023
Research and Development AstraZeneca, Cancer, MSD, NICE, Oncology, lynparza, pharma

UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence (NICE) posted a positive recommendation …

News
merckwindow_web

MSD announce new data from advanced renal cell carcinoma trial

June 8, 2021
Manufacturing and Production MSD, rcc

Merk (MSD) has announced positive data from its Phase III Clear/Keynote-581 trial on Keytruda (pembrolizumab) plus Lenvima (lenvatinib), and Lenvima …

News

NICE rejects Merck Serono’s Bavencio for urothelial cancer

May 10, 2021
Sales and Marketing MSD, Merck, NHS, NICE, cancer treatment, pharma, pharma news

The use of avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy is not recommended by …

News

Merck kidney and uterus cancer treatments granted priority review by FDA

May 7, 2021
Medical Communications FDA, MSD, Merck, cancer treatment, kidney cancer treatment, pharma, pharma news, uterus cancer treatment

The FDA has granted priority review for Merck (MSD) and Eisai’s application for two new approvals for the combination of …

News

Merck cease development of $425 million COVID-19 treatment

April 16, 2021
Medical Communications COVID-19, MSD, Merck, covid-19 treatment, pharma, pharma news

Merck (MSD) have ended the development of their MK-7110 drug for the treatment of hospitalised patients with COVID-19.

News

NHS agrees on MSD interim colorectal cancer treatment

March 25, 2021
COVID-19, Cancer, MSD, NHS

MSD has announced a provisional agreement with the NHS to make KEYTRUDA (pembrolizumab) available for eligible patients with metastatic MSI-H/dMMR …

News

AstraZeneca & MSD ovarian cancer drug combination approved by NICE

March 19, 2021
Medical Communications AstraZeneca, MSD, NICE, oncology

A new precision drug combination, olaparib with bevacizumab, will now be available on the Cancer Drugs Fund (CDF) for ovarian …

News
gilead-sciences

Gilead and MSD partner to develop and commercialise two-drug HIV regimen

March 16, 2021
Manufacturing and Production Gilead, HIV, MSD

Gilead and MSD, known as Merck in the US and Canada, have entered into an agreement to co-develop and co-commercialise …

News
The Gateway to Local Adoption Series

Latest content

Molnlycke donates risk prediction patent to SKF’s digital patent platform

November 14, 2025

Study finds at-home brain stimulation therapies reduce depression relapse rate

November 14, 2025

Smurfit Westrock unveils new clinical packaging facility at Dublin Airport

November 13, 2025

EVerZom enters research and licensing agreement with GENFIT

November 13, 2025

University of Birmingham scientists develop new MRI contrast agent

November 12, 2025